Literature DB >> 24638242

Primary non-small cell lung cancer in a transplanted lung treated with stereotactic body radiation therapy. A case study.

F Oskan1, U Ganswindt, C Belka, F Manapov.   

Abstract

The first case of primary lung cancer in a transplanted lung was described in 2001. Since then, only 5 cases of lung cancer in donated lung have been reported. We present one more patient with non-small cell cancer in the transplanted lung treated with stereotactic body radiation therapy. In most cases of primary lung cancer in transplanted lung, rapid progression of the cancer was reported. Occurrence of the locoregional failure in our case could be explained by factors related to the treatment protocol and also to underlying immunosuppression.

Entities:  

Mesh:

Year:  2014        PMID: 24638242     DOI: 10.1007/s00066-013-0511-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  27 in total

Review 1.  Medical complications of lung transplantation.

Authors:  Dennis M Lyu; Martin R Zamora
Journal:  Proc Am Thorac Soc       Date:  2009-01-15

Review 2.  kV cone-beam CT-based IGRT: a clinical review.

Authors:  Judit Boda-Heggemann; Frank Lohr; Frederik Wenz; Michael Flentje; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2011-04-26       Impact factor: 3.621

Review 3.  Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis.

Authors:  Jian Zhang; Fujun Yang; Baosheng Li; Hongsheng Li; Jing Liu; Wei Huang; Dongqing Wang; Yan Yi; Juan Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-12       Impact factor: 7.038

4.  [Neoplasia in lung transplants].

Authors:  Marina Blanco Aparicio; Carmen Montero Martínez
Journal:  Arch Bronconeumol       Date:  2009-07-09       Impact factor: 4.872

5.  Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer.

Authors:  M Guckenberger; A Kavanagh; M Partridge
Journal:  Strahlenther Onkol       Date:  2012-08-31       Impact factor: 3.621

6.  Donor-acquired small cell lung cancer following pulmonary transplantation.

Authors:  A G De Soyza; J H Dark; D V Parums; A Curtis; P A Corris
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

7.  Observation-only management of early stage, medically inoperable lung cancer: poor outcome.

Authors:  Ronald C McGarry; Guobin Song; Paul des Rosiers; Robert Timmerman
Journal:  Chest       Date:  2002-04       Impact factor: 9.410

8.  Bronchogenic carcinoma after lung transplantation: characteristics and outcomes.

Authors:  Omar A Minai; Sonia Shah; Peter Mazzone; Marie M Budev; Debasis Sahoo; Sudish Murthy; David Mason; Gosta Pettersson; Atul C Mehta
Journal:  J Thorac Oncol       Date:  2008-12       Impact factor: 15.609

9.  Long-term results of lung cancer after heart transplantation: single center 20-year experience.

Authors:  Giuseppe Bruschi; Serena Conforti; Massimo Torre; Tiziano Colombo; Claudio F Russo; Giovanna Pedrazzini; Maria Frigerio; Mario Ravini
Journal:  Lung Cancer       Date:  2008-06-20       Impact factor: 5.705

10.  Long-term survival of heart transplant recipients with lung cancer: the role of chest computed tomography screening.

Authors:  S Mohammadi; N Bonnet; P Leprince; E Charbonneau; G Berberian; M Aslani; G Silvaggio; R Dorent; A Pavie; I Gandjbakhch
Journal:  Thorac Cardiovasc Surg       Date:  2007-10       Impact factor: 1.827

View more
  2 in total

1.  Dynamic tumor-tracking stereotactic body radiation therapy for a solitary tumor in a transplanted organ: two case reports.

Authors:  Shun Okabayashi; Yukinori Matsuo; Noriko Kishi; Hideki Hanazawa; Takashi Mizowaki
Journal:  Int Cancer Conf J       Date:  2020-06-29

2.  Stereotactic ablative radiotherapy for early-stage lung cancer following double lung transplantation.

Authors:  Hanbo Chen; Jussi Tikkanen; R Gabriel Boldt; Alexander V Louie
Journal:  Radiat Oncol       Date:  2018-08-07       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.